文献速递慢性静脉疾病

淋巴水肿泵在有症状下肢水肿患者中的以患者为中心结局

Patient-Centered Outcomes of a Lymphedema Pump in Patients with Symptomatic Lower Extremity Edema.
PubMed 文献 · Ann Vasc Surg · 2024-07-14

本研究评估先进气动压缩装置(APCD)Flexitouch 治疗下肢静脉淋巴水肿的患者报告结局。52 例患者填写问卷,肿胀和疼痛主观改善率分别为 91.4%(P<0.00001)和 85.7%(P=0.00002),装置易用性 85.7%(P=0.00002),作者推荐可考虑将其用于双侧下肢静脉淋巴水肿的管理。

要点

  • 52 例下肢静脉淋巴水肿患者使用 Flexitouch 先进气动压缩装置。
  • 患者主观肿胀改善 91.4%(P<0.00001),疼痛改善 85.7%(P=0.00002)。
  • 装置易用性 85.7%(P=0.00002);作者推荐可考虑用于双侧下肢静脉淋巴水肿管理。

核心结论

  • Flexitouch 先进气动压缩装置使用呈现良好的患者报告结局总体趋势,患者对肿胀、疼痛、装置易用性、培训依从性和使用依从性的主观改善均具统计学显著性,作者推荐可考虑将其用于双侧下肢静脉淋巴水肿的管理。

研究设计与样本

  • 在纽约市健康与医院合作组织内一家急性护理机构开展的研究,纳入 2021 年 12 月至 2023 年 3 月接受 Flexitouch(FLX)先进气动压缩装置治疗的下肢静脉淋巴水肿患者,通过简短问卷评估患者主观结局,采用卡方检验分析,共纳入 52 例参与者。

主要发现

  • 52 例参与者中男性占 30.8%、女性占 69.2%,平均年龄 71.7 岁,全部研究人群均诊断为慢性静脉功能不全背景下的双侧下肢淋巴水肿。
  • 患者感知的肿胀改善率为 91.4%(P<0.00001),疼痛改善率为 85.7%(P=0.00002),FLX 装置易用性报告率为 85.7%(P=0.00002)。
  • 多数患者报告接受过 FLX 使用培训(69.2%,P=0.005)并保持装置使用依从性(67.3%,P=0.012)。

临床怎么用

  • 作者认为 FLX 装置似乎受到患者正面接受,并推荐可考虑将其用于双侧下肢静脉淋巴水肿的管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Phlebolymphedema is a challenging condition to manage, with limited options for effective treatment. For patients, this may be debilitating and lead to infection, loss of independence and affect quality of life. This study aims to evaluate patient-reported outcomes of an advanced pneumatic compression device (APCD) in the treatment of lower extremity phlebolymphedema. METHODS: Patients with diagnosis of lower extremity phlebolymphedema at an acute care facility within the New York City Health and Hospitals Cooperation treated with the Flexitouch (FLX) (Tactile Systems Technology, Inc, Minneapolis, Minnesota) APCD from December 2021 to March 2023 were evaluated. Patient-perceived subjective outcomes were assessed via a short questionnaire, with subsequent analysis using chi-squared test. Primary end points were subjective improvements in 1) swelling, 2) pain, and 3) ease of use of device as surrogates for patient satisfaction. Secondary end point was subjective patient-reported compliance, obtained by investigating 1) if patients were trained to use device, and 2) if patients were using the device. RESULTS: A total of 52 participants were included in this study, consisting of 30.8% male and 69.2% female patients with a mean age of 71.7 years. While selection criteria did not exclude unilateral disease or alternative etiologies, we note that the entire study population had been diagnosed with bilateral lower extremity lymphedema in the setting of chronic venous insufficiency. Other patient characteristics including race, comorbidities and smoking status were documented in Table 1. Table 2 demonstrates the results of chi-squared analysis. This study noted significant patient-perceived improvement in swelling and pain (91.4% with P < 0.00001; 85.7% with P = 0.00002 respectively) and patient-reported ease of use of the FLX device (85.7% with P = 0.00002). Additional secondary findings included a majority of patients reporting being trained on how to use FLX and also maintaining compliance with the device (69.2% with P = 0.005; 67.3% with P = 0.012 respectively). CONCLUSIONS: FLX APCD use has been found to demonstrate desirable patient-reported outcomes as a general trend. The participants in this study noted statistically significant subjective improvement in swelling and pain, ease of use of device and adherence to training and compliance with device. FLX appears to be positively received by patients, and the authors recommend its consideration for management of bilateral lower extremity phlebolymphedema.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Murray-Ramcharan M, Escurra MF, Donaldson B, et al. Patient-Centered Outcomes of a Lymphedema Pump in Patients with Symptomatic Lower Extremity Edema. Ann Vasc Surg. 2024. PMID: 39004279. doi:10.1016/j.avsg.2024.04.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。